DanDi Bioscience

https://news.mt.co.kr/mtview.php?no=2022061314464898472  

This post has been translated from the original article dated 6/13/2022. 

HLB Science, a company specializing in peptide-based new drug development, has started to develop a global sepsis treatment in earnest. HLB Science announced on the 13th that it had submitted a phase 1 clinical trial plan (IND) to the French Ministry of Food and Drug Safety (ANSM) for the development of new drugs for sepsis and gram-negative superbacterial infections on the 10th.

HLB Science's septicemia treatment 'DD-S052P' is a synthetic peptide-based substance with a dual mechanism of killing bacteria and removing endotoxins. It treats sepsis with a dual mechanism that not only directly kills super bacteria, the cause of sepsis, but also removes endotoxin released by killing gram-negative bacteria.

Sepsis is attributed to a cytokine storm (immune hypersensitivity reaction) that occurs when immune cells excessively secrete immune substances in response to endotoxin caused by bacteria or viruses. It has been pointed out as the cause of the sudden death of many patients, but it is a field xxxwhere there is no proper diagnosis or treatment.

This phase 1 clinical trial will be conducted at Eurofins Optimed in France, targeting 72 healthy subjects to confirm the safety, tolerability and blood pharmacokinetics of DD-S052P.

CEO Park Young-min said, “The main cause of sepsis is infection by microorganisms, which causes severe inflammation and immune paralysis throughout the body. is a new concept treatment with a dual mechanism of action that removes the causative bacteria of sepsis and neutralizes the endotoxin released by the causative bacteria, and will dramatically increase the survival rate.”

Sepsis is a disease that damages major organs by causing a systemic inflammatory response if the causative bacteria cannot be eliminated in a short time. Worldwide, it is known that 50 million sepsis patients occur each year, and about 11 million people die.

HLB Science plans to promote technology exports to large pharmaceutical bio companies at home and abroad along with entry into phase 2 after phase 1 clinical trials are over next year. In April of last year, Shinhan Investment Corp. was xxxselected as the supervisor for the transfer and listing on the KOSDAQ.